Profound Medical Corp. Issues Preliminary Unaudited Revenues Report for Q4 2024

Profound Medical Corp., a company listed on the Nasdaq Stock Market under the symbol PROF, recently disclosed its unaudited revenues in a press release dated January 8, 2025. The information detailed the preliminary figures for the quarter and year ended December 31, 2024.

The company furnished a copy of the press release, marked as Exhibit 99.1 in a Form 8-K filing with the U.S. Securities and Exchange Commission. It’s important to note that the contents of this filing, including the press release, are not to be considered as “filed” under the Securities Exchange Act of 1934 or incorporated by reference into any future filings, unless explicitly stated otherwise.

This announcement is in compliance with Item 2.02 of Form 8-K, covering Results of Operations and Financial Condition. Additionally, under Item 8.01 of the same form, the company disclosed the release of the press statement as Exhibit 99.1 and an Interactive Data File as Exhibit 104.

As per the submission signed off by Rashed Dewan, Chief Financial Officer of Profound Medical Corp., on January 8, 2025, this disclosure offers investors and stakeholders valuable insights into the company’s financial performance for the specified period.

Investors and market analysts are expected to closely examine the details provided in the press release to assess Profound Medical Corp.’s financial health and performance in the specified period. Such transparency in disclosing financial information reinforces the company’s commitment to maintaining clear communications with its shareholders and the investing public.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Profound Medical’s 8K filing here.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.